Literature DB >> 24559445

Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer.

Adetunji T Toriola1, Egle Tolockiene, Helena Schock, Helja-Marja Surcel, Anne Zeleniuch-Jacquotte, Goran Wadell, Paolo Toniolo, Eva Lundin, Kjell Grankvist, Annekatrin Lukanova.   

Abstract

BACKGROUND: We investigated whether the free β-human chorionic gonadotropin (free β-hCG) would provide additional information to that provided by total hCG alone and thus be useful in future epidemiological studies relating hCG to maternal breast cancer risk. MATERIALS &
METHODS: Cases (n = 159) and controls (n = 286) were a subset of our previous study within the Northern Sweden Maternity Cohort on total hCG during primiparous pregnancy and breast cancer risk.
RESULTS: The associations between total hCG (hazard ratio: 0.79; 95% CI: 0.49-1.27), free β-hCG (hazard ratio: 0.85; 95% CI: 0.33-2.18) and maternal risk of breast cancer were very similar in all analyses and mutual adjustment for either one had minor effects on the risk estimates.
CONCLUSION: In the absence of a reliable assay on intact hCG, total hCG alone can be used in epidemiological studies investigating hCG and breast cancer risk, as free β-hCG does not appear to provide any additional information.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24559445      PMCID: PMC4143888          DOI: 10.2217/fon.13.208

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  31 in total

Review 1.  The classification, functions and clinical use of different isoforms of HCG.

Authors:  Ulf-Håkan Stenman; Aila Tiitinen; Henrik Alfthan; Leena Valmu
Journal:  Hum Reprod Update       Date:  2006-07-28       Impact factor: 15.610

2.  Characterization of the hCG variants recognized by different hCG immunoassays: an important step toward standardization of hCG measurements.

Authors:  Ann M Gronowski; David G Grenache
Journal:  Clin Chem       Date:  2009-06-18       Impact factor: 8.327

3.  Adjustment of serum markers in first trimester screening.

Authors:  Geralyn Lambert-Messerlian; Glenn E Palomaki; Jacob A Canick
Journal:  J Med Screen       Date:  2009       Impact factor: 2.136

Review 4.  Antenatal screening for Down's syndrome.

Authors:  N J Wald; A Kennard; A Hackshaw; A McGuire
Journal:  Health Technol Assess       Date:  1998       Impact factor: 4.014

5.  Serum markers for Down's syndrome in relation to number of previous births and maternal age.

Authors:  N J Wald; H C Watt
Journal:  Prenat Diagn       Date:  1996-08       Impact factor: 3.050

6.  Co-variables in first trimester maternal serum screening.

Authors:  I M de Graaf; H S Cuckle; E Pajkrt; N J Leschot; O P Bleker; J M van Lith
Journal:  Prenat Diagn       Date:  2000-03       Impact factor: 3.050

Review 7.  New discoveries on the biology and detection of human chorionic gonadotropin.

Authors:  Laurence A Cole
Journal:  Reprod Biol Endocrinol       Date:  2009-01-26       Impact factor: 5.211

8.  First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.

Authors:  Jonathan P Bestwick; Wayne J Huttly; Nicholas J Wald
Journal:  J Med Screen       Date:  2008       Impact factor: 2.136

Review 9.  Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights.

Authors:  S F de Medeiros; R J Norman
Journal:  Hum Reprod Update       Date:  2008-10-22       Impact factor: 15.610

10.  Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappaB and AP-1 activation.

Authors:  Ch V Rao; X Li; S K Manna; Z M Lei; B B Aggarwal
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

View more
  2 in total

1.  Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort.

Authors:  Renée T Fortner; Helena Schock; Rudolf Kaaks; Matti Lehtinen; Eero Pukkala; Hans-Åke Lakso; Minna Tanner; Raija Kallio; Heikki Joensuu; Jaana Korpela; Adetunji T Toriola; Göran Hallmans; Kjell Grankvist; Anne Zeleniuch-Jacquotte; Paolo Toniolo; Eva Lundin; Heljä-Marja Surcel
Journal:  Cancer Res       Date:  2016-10-26       Impact factor: 12.701

2.  Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk.

Authors:  Rosie Cornish; Anne Cathrine Staff; Andy Boyd; Debbie A Lawlor; Steinar Tretli; Gary Bradwin; Thomas F McElrath; Marianne Hyer; Robert N Hoover; Rebecca Troisi
Journal:  Cancer Causes Control       Date:  2018-12-01       Impact factor: 2.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.